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In the last two decades, biomedical scientists have
made extraordinary efforts to unravel molecular
intricacies underlying carcinogenesis, thus providing a
strong foundation for the development of targeted
cancer therapies. Application of latest molecular
technologies have transformed our understanding of
cancer pathogenesis and mechanisms involved in
neoplastic transformation.1 Cancer, as known today,
is a disease that has its origin embedded in the
alteration of specific genes. This hypothesis was held
true because several “cancer genes” have been
discovered and characterized using high throughput
molecular technologies.2 Moreover, the completion of
human genome sequencing has placed a major
milestone on this path and as was anticipated in the
initial phase of the genome project, its completion has
led to significant advancements in our understanding of
cancer biology.
Over the last few decades, the identification and
characterization of the genetic changes in malignant
transformation have progressed rapidly. On the other
hand, failure of response to therapy has been
progressively detected; these failures could be due to
drug intolerance, lethal toxicities, insensitivity of target
receptors and genetic changes or alteration in cell
signaling pathways.
Cell surface receptors play crucial role in cancer
biogenesis, especially those receptors that encode
for enzymatic activities, such as tyrosine kinases,
commonly known as receptor tyrosine kinases (RTKs).
These are membrane-spanning cell proteins that play
critical role in transduction of extracellular signals to
cytoplasm.3 There are approximately sixty RTKs, which
are divided into twenty sub-families as defined by their
ligands. Among these receptors three features including
immunoglobulin like sequence having amino terminal
extracellular domain, lipophilic transmembrane segment
and an intracellular carboxyl terminal domain which
contain tyrosine kinase catalytic site are found
common.4
The RTKs are activated through binding with their
ligands, hormones, peptide or growth factors and trigger
a cascade of signaling molecules subsequently leading
to transcription of genes, which regulate cell growth,
proliferation, differentiation, migration and apoptosis. In
addition, RTKs can also become activated by somatic
mutations, which are identified as a common
mechanism of carcinogenesis, whereby they play an
important role in the modulation of growth factors
signaling under pathological conditions. Activated forms
can cause increased tumor cell proliferation, growth
induce anti-apoptotic effects and promote angiogenesis.
Therefore, detection of RTK variants in malignancies is
not only useful for the diagnosis but also becomes
helpful in their treatment, as specific markers of targeted
therapies.2
In cancer therapy, during the last decade, a major
development was the advent of Tyrosine Kinase
Inhibitors (TKI), these small molecules inhibit patho-
logically induced activation of RTKs. Till date, several
RTKs can be targeted by small molecule inhibitors, and
clinical evidence indicates that tumors carrying
mutations involving RTK genes are particularly
susceptible to such inhibitors, most probably because
of tumors becoming “addicted'' to specific kinase
pathways. The advantages of TKI over conventional
chemotherapy are numerous; such as this treatment is
specific for cancer cells and it is less toxic and it can be
utilized at any age and every stage of the disease with
minimal harm to body's physiological functions. TKIs
have been approved for several malignancies in both
hematolymphoid and solid tumor groups.1
The first successfully used TKI, Imatinib Mesylate
(Gleevec), was very effective in treating Chronic Myeloid
Leukemia (CML). This success led to an accelerated
approval of this drug in 2001. Currently, the predicted
survival time of CML patients has improved from 15
months before Imatinib to a projected 15 years after the
latter's introduction.5 With the passage of time, the list of
TKIs have expanded as well as their application in
various cancers particularly lung cancer, breast cancer,
gastrointestinal stromal tumor, and female genital
tumors.
One of the disadvantage of this biological treatment,
which by definition is non-cytotoxic and can thus be
chronically administrated, is the development of
resistance. During the course of treatment, response to
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TKI is generally slow, which could be due to extrinsic
mechanisms involving metabolism of drug, bioavail-
ability or systemic deterioration due to progressive
illness. In addition, intrinsic factors can also have major
impact on drug response, like acquired mutations
developed during the course of therapy seen in CML,
lung tumors, breast tumors, hepatic and renal cancers.
In a tumor where a single dominant oncogene, such as
the RTK, is activated by mutations; acquired resistance
is the consequence of secondary mutations generally
affecting the kinase domain of the receptors. This
ultimately results in the modification of the kinase
conformation, which becomes no longer compatible with
the TKI-binding.
To overcome the failure of therapy, the initial approach
includes escalation of TKI dose, but it is usually
associated with side effects and intolerance. New
emerging second line TKIs are more potent, most of
them have dual target/receptor action with high efficacy.6
The combination of second line with first line TKIs was
found significantly more effective and less toxic in
various clinical trials.6
In future, prospective use of molecular modeling and
simulation for the selection of new TKIs is likely to pave
the way towards a truly personalized treatment. The
upcoming future technologies have the potential for
designing multi-targeted therapeutic agents with the
ability to effectively inhibit both primary and/or expected
secondary mutations.7 The new agents in the pipeline
include multi-targeted TKIs and non-selective inhibitors
of tyrosine kinases. Majority of these are currently in pre-
clinical workup or phase I/II trials and hopefully, these
agents will soon become available for treatment of
cancer patients as mono or combination therapies.
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